Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs-Reference-Cited by-同舟云学术

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Published:2017-06-12 Issue:7 Volume:31 Page:585-602
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Jongen Peter Joseph

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

http://link.springer.com/article/10.1007/s40263-017-0444-x/fulltext.html

Reference108 articles.

1. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72:132–41.

2. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40.

3. Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 2017. doi: 10.1136/jim-2016-000339 .

4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology. 1983;33(11):1444–52.

5. Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims; 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf . Accessed 10 May 2017.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

2. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study;Frontiers in Neurology;2024-07-18

3. Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study;The Egyptian Journal of Neurology, Psychiatry and Neurosurgery;2024-06-20

4. Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study;Multiple Sclerosis and Related Disorders;2024-06

5. Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: Data from the Argentinean registry;Multiple Sclerosis and Related Disorders;2024-05